Press Release: Basilea announces commercial -2-

Basilea Pharmaceutica

44.70 CHF 11.25%

• Charts
• News
• Analysen

Kaufen Verkaufen

Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection associated with significant morbidity and mortality.(3) Complications include concomitant infections such as bone, joint or heart valve infections, persistent bacteremia or bacteremia in patients on dialysis. With a 30-day all-cause mortality of around 20% there is a high medical need for improved therapies for SAB.(4)

About acute bacterial skin and skin structure infections (ABSSSI)

Acute bacterial skin and skin structure infections (ABSSSI) are common infections in the healthcare setting. Staphylococcus aureus is the most common pathogen associated with these infections, which can be difficult to treat if methicillin-resistant Staphylococcus aureus (MRSA) is involved.(5)

About community-acquired bacterial pneumonia (CABP)

Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality worldwide. It is the leading cause of infectious disease-related death in the US.(6)

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO(R) (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA(R) (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA(R) (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA(R) (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the US.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit https://www.globenewswire.com/Tracker?data=eCELRpczWizrA4g7urCtCESdOCmrz-GNdcIYr0nNdlmtLSZUZ_ZYF8ETqjSWvCAWDPU80aM1J-EiU2aeEemS7Q== basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland

Phone +41 61 606 1102

E-mail media_relations@basilea.com

investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

1. Summary of Product Characteristics (SmPC) Zevtera:

https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: May 19,

2025]

2. Full US prescribing information:

https://innovivaspecialtytherapeutics.com/wp-content/uploads/2025/05/Prescribing-Information-Zevtera.pdf

[Accessed: May 19, 2025]

3. A. P. Kourtis, K. Hatfield, J. Baggs et al. Vital signs: Epidemiology and

recent trends in methicillin-resistant and in methicillin-susceptible

Staphylococcus aureus bloodstream infections -- United States. Morbidity

and Mortality Weekly Report 2019 (68), 214-219

4. K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus

daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a

double-blind, Phase III trial. Future Microbiology 2020 (1), 35-48

5. J. Edelsberg, C. Taneja, M. Zervos et al. Trends in US hospital

admissions for skin and soft tissue infections. Emerging Infectious

Diseases 2009 (15), 1516-1518

6. J. A. Ramirez, T. L. Wiemken, P. Peyrani et al. Adults hospitalized with

pneumonia in the United States: Incidence, epidemiology, and mortality.

Clinical Infectious Diseases 2017 (65), 1807-1812

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/a7a96be2-bdd4-477a-8f76-3266f43ae642

(END) Dow Jones Newswires

May 20, 2025 01:15 ET (05:15 GMT)